A phase Ib study of a novel c-MET, AXL and VEGFR-2 inhibitor ningetinib and gefitinib combination therapy in Chinese EGFR-TKI resistant NSCLC with T790M negative.

Hongyun Zhao,Lianke Liu,Yuxiang Ma,Jian Fang,Wenfeng Fang,Haiqing Ma,Yang Zhang,Guosheng Feng,Shaodong Hong,Shan Zeng,Bo Xie,Jun Ren,Xiaoyan Lin,Yingjun Zhang,Ning Xi,Yingzhi Jiang,Yanjun Wu,Ning Kang,Su Li,Li Zhang

A phase Ib study of a novel c-MET, AXL and VEGFR-2 inhibitor ningetinib and gefitinib combination therapy in Chinese EGFR-TKI resistant NSCLC with T790M negative.

2020

Hongyun Zhao
Lianke Liu
Yuxiang Ma
Jian Fang
Wenfeng Fang
Haiqing Ma
Yang Zhang
Guosheng Feng
Shaodong Hong
Shan Zeng
Bo Xie
Jun Ren
Xiaoyan Lin
Yingjun Zhang
Ning Xi
Yingzhi Jiang
Yanjun Wu
Ning Kang
Su Li
Li Zhang

9583Background: Ningetinib is a novel tyrosine kinase inhibitor, targeted at c-Met, Axl, VEGFR-2, Mer and Flt3. This phase Ib trial (NCT03758287) evaluated the safety, determined the recommended ph...

Keywords:

C-Met
T790M
Pathology
Gefitinib
Combination therapy
egfr tki
VEGF receptors
Cancer research
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations